Watch the CMM Castilla-La Mancha Media interview about our work with Artemisia annua and its possible application in the fight against the virus.
Our company Tricopharming was included by the ABC newspaper in the top of the biotechnology and ICT companies that are committed to development and innovation in Spain thanks to our biotechnology based on biopharmaceutical agriculture and our first success case Artennua®, a optimized version of Artemisia annua. Read the complete ABC newspaper note here.
Glad to announce that Tricopharming has been selected among the 20 most innovative tech startups of Catalonia Region within the framework of the Startup Capital 2019 call! Startup Capital boosts early stage technological companies helping to accelerate their product development and road map to market by co-financing business plan implementation. The call is addressed to…
Our Artennua plant, an optimized version of Artemisia annua is trending thanks to the great potential of its Artemisinin molecule as a possible treatment for Covid-19. Watch at the Radio Television Canaria RTVC note about our work.
Look at the journalistic note of El Economista about the great power of our #Artemisiaannua plant grown on our ecological farm in Tenerife.
Artemisia annua plant contains more than 400 metabolites. Among them, stands out the molecule artemisinin, the most effective antimalarial treatment to date. Could Artemisia annua and/or artemisinin molecule be a good candidate to fight Covid-19? This TV news contributes to the debate with our CEO Luís Matías Hernández, PhD, and our Agricultural Engineer Andrés Acosta…
Thanks to CDTI and our achievement at Cervera project, we have been working on our production platform for biomolecules of Industrial interest. We will continue working on the validation of our biostimulation technology in various species of Medicinal and Aromatic plants (MAPs), as well as we have done with Artemisia annua plant. Learn more about…
Biotech Tricopharming Research wins its first Fyde CajaCanarias Emprendedores 2019 award.
Program SER Castilla-La Mancha A scientist from Cuenca, a medicinal plant and a treatment against malaria.
Sequentia Biotech creates the spin-out Biotech Tricopharming Research to market Artennua, its first biopharmaceutical agriculture product.
Artennua (formerly known as ArtePharming)
Artennua (formerly known as ArtePharming) has been selected as a finalist in three of the most prestigious international awards for social entrepreneurs:
The Tricopharming R&D project has received funding from Cervera Project (CDTI), MINECO and the Generalitat de Catalunya.
Our Publications and their impact in the news
Matias-Hernandez et al., 2017. Matias-Hernandez L., Jiang W., Yang K., Tang K., Brodelius P., Pelaz S. AaMYB1 and its orthologue AtMYB61 affect terpene metabolism and trichome development in Artemisia annua and Arabidopsis thaliana. Plant Journal (2017), 90(3):520-534.
Pulice et al., 2016. Pulice G., Pelaz S., Matias-Hernandez L. Molecular Farming in Artemisia annua, a promising approach to improve Anti-malarial drug production. Frontiers in Plant Science (2016), 18:7;329.
LaVanguardia
ElMundo
Science Times
Eureka.
Artennua news (formerly known as ArtePharming)
RTVE
RTVE Audio
El País
El Español
TV3.
